Diabetes doubles risk for heart failure
An analysis of health records of the whole Scottish population aged ?30 years revealed that people with diabetes have an increased risk for heart failure.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2193 entries already.
Entries by Thomas Gabrielczyk
AZ checkpoint blocker combo fails in head and neck cancer
British drugmaker AstraZeneca (AZ) has missed another opportunity to secure a share in the lucrative immunoncology market: a Phase III trial combining durvalumab with tremelimumab missed the survival endpoint.
XyloCor Therapeutics bags US$17m in Series A financing
LSP and Sofinnova Ventures co-led the financing of the Amsterdam-based gene therapy specialist XyloCor Therapeutics.
Uncommon mutations affect breast cancer prognosis
Uncommon mutations in three genes in estrogen receptor positive breast cancer have a negative impact on disease prognosis reports a team of British and Australian researchers in Nature Communications.
GSK swallows Tesaro in US$5.1bn deal
GlaxoSmithKline said it will pay $75 per share in cash to take over US oncology player Tesaro, whose FDA-approved DNA repair blocker nirparib (Zejula) made only US$166m in sales in Q1-3/2018.
Argenx in US$1.6bn deal with J&J affiliate Janssen
Janssen affiliate Cilag GmbH International has licenced argenx’ anti-CD70 antibody cusatuzumab (ARGX-110) for US$300m upfront.
Driver of GVHD after blood stem cell transplantation identified
Swiss, French and German researchers have unraveled a molecular pathway that might be useful to prevent Graft-versus-Host Disease (GVHD) in leukemic recipients of blood stem cell transplants.
Closing a gap at ICUs
Diagnostic results must be readily available to diagnose critically ill patients in emergency settings and at ICUs. So far, diagnostic blood tests, which demonstrably could help emergency meds recognise residual congestion in heart failure, septic shock, or acute kidney injury before patients reach critical condition, have not been available in the automated format required at ICUs. After Sphingotec acquired Nexus IB-10 POC testing platform in May, investors wait in line.
Carbios set to build closed-loop PET plant
French Carbios SA has signed a letter of intent with PVC giant Kem One to implement a demonstration plant to provide proof of concept of Carbios groundbreaking enzymatic PET depolymerisation technology.
Adrenomed bags €24m in growth financing
German Adrenomed AG has bagged €24m in equity financing from HBM Healthcare Investments and Wellington Partners.